Sutton Wealth Advisors Inc. Exelixis, Inc. Transaction History

Sutton Wealth Advisors Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 07, 2023	SELL	$16.3 - $19.41 $244 - $291	-15 Closed	0 $0
Q4 2022 Nov 07, 2023	SELL	$14.96 - $17.39 $748 - $869	-50 Reduced 76.92%	15 $241,000
Q3 2022 Nov 07, 2023	BUY	$15.68 - $22.27 $15 - $22	1 Added 1.56%	65 $1.02 Million
Q2 2022 Nov 07, 2023	BUY	$17.44 - $23.16 $348 - $463	20 Added 45.45%	64 $1.33 Million
Q1 2022 Nov 07, 2023	BUY	$17.03 - $22.67 $187 - $249	11 Added 33.33%	44 $997,000
Q4 2021 Nov 07, 2023	BUY	$15.84 - $21.88 $522 - $722	33 New	33 $603,000
Q1 2018 Nov 06, 2023	SELL	$22.15 - $31.89 $9,746 - $14,031	-440 Closed	0 $0
Q4 2017 Nov 06, 2023	BUY	$24.23 - $30.93 $10,661 - $13,609	440	440 $13.4 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Sutton Wealth Advisors Inc., based on Form 13F filings with the SEC.

Stay updated on Sutton Wealth Advisors Inc. with notifications on news.